754 related articles for article (PubMed ID: 32396773)
1. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
[TBL] [Abstract][Full Text] [Related]
4. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
Lata S; Akif M
J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
[TBL] [Abstract][Full Text] [Related]
5. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
Dehury B; Raina V; Misra N; Suar M
J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
[TBL] [Abstract][Full Text] [Related]
6. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
7. In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2.
Hakmi M; Bouricha ELM; Akachar J; Lmimouni B; El Harti J; Belyamani L; Ibrahimi A
J Biomol Struct Dyn; 2022 Mar; 40(4):1546-1557. PubMed ID: 33023417
[TBL] [Abstract][Full Text] [Related]
8. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
9. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
10. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
[TBL] [Abstract][Full Text] [Related]
11. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
[TBL] [Abstract][Full Text] [Related]
12. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
Kalathiya U; Padariya M; Fahraeus R; Chakraborti S; Hupp TR
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671255
[TBL] [Abstract][Full Text] [Related]
13. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
[TBL] [Abstract][Full Text] [Related]
14. The molecular dynamics of possible inhibitors for SARS-CoV-2.
Irani AH; Steyn-Ross DA; Steyn-Ross ML; Voss L; Sleigh J
J Biomol Struct Dyn; 2022; 40(20):10023-10032. PubMed ID: 34229582
[TBL] [Abstract][Full Text] [Related]
15. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
16. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
18. An
Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
[TBL] [Abstract][Full Text] [Related]
19. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
Rui L; Haonan L; Wanyi C
Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
[TBL] [Abstract][Full Text] [Related]
20. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]